UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549





FORM 10-Q/A

(AMENDMENT NO. 1)





(Mark One)

|x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|- | ---------------------------------------------------------------------------------------

For the quarterly period ended March 31, 2016



| ̈ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|- | ----------------------------------------------------------------------------------------

For the transition period from
                     to

Commission file number: 001-36508





KITE PHARMA,
INC.

(Exact Name of Registrant as Specified in Its Charter)







|                                                               |  |                                     
|-------------------------------------------------------------- |  | ------------------------------------
|Delaware                                                       |  | 27-1524986                          
|(State or Other Jurisdiction of
Incorporation or Organization) |  | (I.R.S. Employer
Identification No.)
|                                                               | 
|2225 Colorado Avenue
Santa Monica, California                  |  | 90404                               
|(Address of Principal Executive Offices)                       |  | (Zip Code)                          

(310) 824-9999

(Registrants Telephone Number, Including Area Code)





Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No  ̈

Indicate by check mark whether
the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T
(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such
files).    Yes  x    No   ̈

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):



|                        |  |                                                  |  |                           |  |  
|----------------------- |  | ------------------------------------------------ |  | ------------------------- |  | -
|Large accelerated filer |  | x                                                |  | Accelerated filer         |  |  ̈
|                        |  |                                                  | 
|Non-accelerated filer   |  |  ̈  (Do not check if a smaller reporting company) |  | Smaller reporting company |  |  ̈

Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange
Act).    Yes   ̈    No  x

As of May 5, 2016, the number of outstanding shares of the registrants common stock, par value $0.001 per share, was 49,129,352.









---

EXPLANATORY NOTE

This Amendment No. 1 to Form 10-Q/A (this Amendment) amends the Quarterly Report on Form 10-Q of Kite Pharma, Inc. (the Company) for the quarter ended March 31, 2016, originally filed with the Securities and Exchange Commission on May 9, 2016 (the Original
Filing). This Amendment is being filed solely to include revised Exhibits 31.1 and 31.2, which replace the previously filed versions of those exhibits, to include certain statements required by Item 601(b)(31) of Regulation S-K inadvertently omitted when previously filed.

Except as described as above, no changes have been
made to the Original Filing. The Original Filing continues to speak as of the date of the Original Filing, and the Company has not updated the disclosures contained therein to reflect any events that have occurred as of a date subsequent to the date
of the Original Filing. Accordingly, this Amendment should be read in conjunction with the Original Filing and the Companys filings made with the SEC subsequent to the filing of the Original Filing. The filing of this Amendment is not an
admission that the Original Filing, when filed, included any untrue statement of a material fact or omitted to state a material fact necessary to make a statement not misleading.



---

|ITEM 6. | EXHIBITS
|------- | --------

The following exhibits are filed as part of this report:



|       |  |                                                                                                                                              
|------ |  | ---------------------------------------------------------------------------------------------------------------------------------------------
|Number |  | Description                                                                                                                                  
|       | 
|31.1   |  | Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as
amended.
|       | 
|31.2   |  | Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as
amended.



---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.



|              |  |  |  |                   |  |                                      
|------------- |  |  |  | ----------------- |  | -------------------------------------
|              |  |  |  | KITE PHARMA, INC.
|              |  |  | 
|June 28, 2016 |  |  |  | By:               |  | /s/ Arie Belldegrun, M.D.            
|              |  |  |  |                   |  | Arie Belldegrun, M.D.                
|              |  |  |  |                   |  | President and Chief Executive Officer
|              |  |  | 
|June 28, 2016 |  |  |  | By:               |  | /s/ Paul L. Jenkinson                
|              |  |  |  |                   |  | Paul L. Jenkinson                    
|              |  |  |  |                   |  | Chief Financial Officer